US6080421A - Transdermal therapeutic system identified without printing inks - Google Patents
Transdermal therapeutic system identified without printing inks Download PDFInfo
- Publication number
- US6080421A US6080421A US08/981,133 US98113398A US6080421A US 6080421 A US6080421 A US 6080421A US 98113398 A US98113398 A US 98113398A US 6080421 A US6080421 A US 6080421A
- Authority
- US
- United States
- Prior art keywords
- layer
- transdermal therapeutic
- therapeutic system
- coding
- backing layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 22
- 238000007639 printing Methods 0.000 title abstract description 8
- 239000000976 ink Substances 0.000 title description 5
- 239000013543 active substance Substances 0.000 claims abstract description 10
- 239000011159 matrix material Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000012815 thermoplastic material Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000003746 surface roughness Effects 0.000 claims description 3
- 238000005299 abrasion Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 230000002085 persistent effect Effects 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 238000002372 labelling Methods 0.000 abstract description 4
- 229920003023 plastic Polymers 0.000 abstract description 4
- 239000004033 plastic Substances 0.000 abstract description 4
- 239000000049 pigment Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract 1
- 230000002110 toxicologic effect Effects 0.000 abstract 1
- 231100000027 toxicology Toxicity 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 18
- 239000000463 material Substances 0.000 description 5
- 229920000139 polyethylene terephthalate Polymers 0.000 description 5
- 239000005020 polyethylene terephthalate Substances 0.000 description 5
- 229920001169 thermoplastic Polymers 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 4
- -1 polyethylene terephthalate Polymers 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000004049 embossing Methods 0.000 description 3
- 239000005038 ethylene vinyl acetate Substances 0.000 description 3
- 239000004753 textile Substances 0.000 description 3
- 239000004416 thermosoftening plastic Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000002650 laminated plastic Substances 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000002966 varnish Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000010023 transfer printing Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Definitions
- the invention relates to a transdermal therapeutic system for delivering active agents to the human body through the skin.
- Transdermal therapeutic systems have already been introduced in the market for the pharmaceutical treatment of a number of diseases and have proven themselves in practice.
- an essentially impermeable, non-sticking backing layer (1) is used for protection against unwanted delivery of the active agent or skin moisture by the transdermal therapeutic system and also for protection against adhesion to textiles.
- the backing layer consists of the usual pharmaceutical materials, such as plastic webs, papers, nonwovens or textiles. Frequently, thermoplastic plastics are used because of their easy processability, such as extruding or casting, stretching along the length or cross in the case of films or also in form of fibers in their use as non-woven-like or textile applications.
- PETP polyethylene terephthalate
- PE polyethylene
- HDPE high density polyethylene
- PVC polyvinyl chloride
- EVA ethylene-vinyl acetate-copolymers
- PP polypropylene
- laminates can be used (for example EVA or PE (outer surface) and PETP).
- the surface (4) can be (PE or EVA) equipped with skin-like soft "touch” and on the other side, a PETP layer (5) may act as a diffusion barrier against the active substance of the transdermal therapeutic system.
- thermoplastic plastics are deformable under heat and a change of shape may be used to emboss patterns or information on everyday commodities, and also on plastic laminates (see e.g., U.S. Pat. No. 4,359,442).
- embossing is known as a procedure to label transdermal therapeutic systems (DE-Gbm 94 9 784).
- a sheet-like means of labeling with embossments or prints are applied on the drug-containing part of patches containing pharmaceutical agents.
- a number of varnishes do not or only insufficiently stick on the backing material; this way only printable materials are suitable.
- the printing ink on the transdermal therapeutic systems may soften during storage and the imprint becomes unreadable upon the influence of volatile agents in the transdermal therapeutic system.
- a color print code on the transdermal therapeutic system is disturbing cosmetically for the consumer.
- embossing is chosen for application of the coding, at application of ordinary techniques accessible for those skilled in the art, the drug-containing part has to be exposed to an undue and high pressure, noxious for the pharmaceutical form of application.
- the task of the present invention is, therefore, a transdermal therapeutic system consisting of a backing layer of thermoplastic material consisting of a laminate of a low-melting thermoplastic material on the external surface and a higher melting thermoplastic material facing the skin side, and a persistent, identifying code applied on this laminate, as well as an active part containing the active agent, which allows a safe labeling on said backing layer without the use of further additives.
- this coding consists of a locally different surface property, surface thickness or surface roughness.
- Such substances are nicotine, nitroglycerine, for example, are examples of pharmaceutical agents.
- Ethanol, propylene glycol and other low molecular alcohols, menthol, eucalyptol, limonene and many other terpenes, low molecular fatty acids such as capric acid and dimethyl sulfoxide are named exemplarily as typical additives in transdermal therapeutic systems which represent a risk factor for classical printing technology.
- a disadvantageous change of drug content occurs upon the influence of temperature.
- the invention is represented in FIG. 1 in detail.
- other typical elements of such pharmaceutical forms of application and element groups may be used without impairing the inventive solution.
- FIG. 1 shows a transdermal therapeutic system in cross-section with backing layer (1) divided up into printable thermoplastic layer (4) and diffusion-(and temperature-) barrier (5).
- the transdermal therapeutic system can also have a removable protecting layer (3).
- the transdermal therapeutic system contains, therefore, the elements:
- Backing layer consisting of (4) and (5), with coding
- coding is provided on the printable thermoplastic layer (4) of the backing layer.
- the coding consists of a locally different surface property, surface thickness or surface roughness of the backing layer. Coding on the backing layer may be generated by methods such as pressure, heat, ultrasound or abrasion. Such methods are known to those skilled in the art.
- the coding is typically performed after the transdermal therapeutic system has been formed.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Laminated Bodies (AREA)
Abstract
The invention refers to a transdermal therapeutic system for the delivery of active agents to the human body.
The backing layer consists of common pharmaceutical plastic layer laminates which require labeling, e.g. by printing. The problem to solve lies in toxicological, technological and drug law disadvantages of pigment- or varnish-printing.
According to the invention, the coding does not consist of an ink- or pigment layer but in an effect on surface properties of the backing layer corresponding to the coding.
Description
This application is a 371 of PCT/DE96/00699, filed Apr. 23, 1996.
The invention relates to a transdermal therapeutic system for delivering active agents to the human body through the skin.
Transdermal therapeutic systems have already been introduced in the market for the pharmaceutical treatment of a number of diseases and have proven themselves in practice.
Moreover, a number of different possible system designs are known in the art (see for example Y. W. Chien in: A. F. Kydonieus and B. Berner (eds.) "Transdermal Delivery of Drugs", p. 81-100).
There are some fundamental similarities, however, independent of the variety of possible system designs between the systems known in the art these similarities are:
1. For protection against unwanted delivery of the active agent or skin moisture by the transdermal therapeutic system and also for protection against adhesion to textiles, an essentially impermeable, non-sticking backing layer (1) is used.
2. Since transdermal therapeutic systems have to stick on the skin, the layer facing the skin, and occasionally only a part of the area facing the skin is made from a pressure-sensitive adhesive.
3. Because of these self-adhesive qualities, a removable protective layer (3) made from a non-adhesive material, if necessary, is added to the transdermal therapeutic system.
The backing layer consists of the usual pharmaceutical materials, such as plastic webs, papers, nonwovens or textiles. Frequently, thermoplastic plastics are used because of their easy processability, such as extruding or casting, stretching along the length or cross in the case of films or also in form of fibers in their use as non-woven-like or textile applications.
Specifically suited plastics are exemplified by polyethylene terephthalate (PETP) and other polyesters, polyethylene (HDPE or LDPE), polyvinyl chloride (PVC, optional softenized), ethylene-vinyl acetate-copolymers (EVA) and polypropylene (PP). In order to combine advantageous features, laminates can be used (for example EVA or PE (outer surface) and PETP). The surface (4) can be (PE or EVA) equipped with skin-like soft "touch" and on the other side, a PETP layer (5) may act as a diffusion barrier against the active substance of the transdermal therapeutic system.
Similarly, as in the case of conventional pharmaceutical application forms, the marketing companies, the regulatory agencies or consumer organizations wish or even require the clear identification of the systems. In this way, a positive identification of the product is necessary when the package leaflet and other accompanying information is not available. Form, size and appearance alone cannot ensure positive identification.
It has become therefore conventional in the art to print such systems with a suitable printing ink on the outside of the backing layer. This possibility, described in EP 0 114 125, allows easy identification and makes colored noticeable features possible.
Furthermore, it is known by those skilled in the plastics art that thermoplastic plastics are deformable under heat and a change of shape may be used to emboss patterns or information on everyday commodities, and also on plastic laminates (see e.g., U.S. Pat. No. 4,359,442).
For the labeling of articles, especially in the packing of pharmaceutical products, however, only transfer printing is usually used in which a pigmented plastic laminate is pressed for a short period of time against the matter to be printed. This allows the ink pigment to be applied onto the substrate.
Also embossing is known as a procedure to label transdermal therapeutic systems (DE-Gbm 94 9 784). Here, a sheet-like means of labeling with embossments or prints are applied on the drug-containing part of patches containing pharmaceutical agents.
This state of the art nevertheless has a number of disadvantages: with the use of (only toxicologically acceptable) printing inks, to work with solvent-containing carrier fluids for pigments and varnishes at the place of the manufacture of pharmaceutical products is problematic because of possible contamination with foreign materials.
A number of varnishes do not or only insufficiently stick on the backing material; this way only printable materials are suitable.
The printing ink on the transdermal therapeutic systems may soften during storage and the imprint becomes unreadable upon the influence of volatile agents in the transdermal therapeutic system.
Furthermore, a color print code on the transdermal therapeutic system is disturbing cosmetically for the consumer.
If, as in DE-Gbm 94 9 784, embossing is chosen for application of the coding, at application of ordinary techniques accessible for those skilled in the art, the drug-containing part has to be exposed to an undue and high pressure, noxious for the pharmaceutical form of application.
Compression of the matrix in this way easily leads to local changes of the function of the patch, particularly the release in vitro. An embossment performed prior to application of a sheet-like carrier of label requires a second pressure sensitive adhesive intermediate layer which usually leads to a bubble-containing unattractive appearance.
The embossment mentioned in DE-Gbm 94 09 784 is not described technically more precisely in the detail there. The use of a backing made of a uniform polymer material, which is the predominant use, an embossment, in any way performed, with or without the action of heat, causes the production of "thin areas". This may destroy the barrier property of the backing for the active agent and obviously, for this reason, embossing is not done in practice.
The task of the present invention is, therefore, a transdermal therapeutic system consisting of a backing layer of thermoplastic material consisting of a laminate of a low-melting thermoplastic material on the external surface and a higher melting thermoplastic material facing the skin side, and a persistent, identifying code applied on this laminate, as well as an active part containing the active agent, which allows a safe labeling on said backing layer without the use of further additives.
According to this invention, the task is settled by the fact that this coding consists of a locally different surface property, surface thickness or surface roughness.
The advantages of this invention are observed particularly with active agents or other ingredients which are volatile at the storage temperature and, therefore, may migrate through the gas space of the transdermal therapeutic system according to the state of the art.
Such substances are nicotine, nitroglycerine, for example, are examples of pharmaceutical agents. Ethanol, propylene glycol and other low molecular alcohols, menthol, eucalyptol, limonene and many other terpenes, low molecular fatty acids such as capric acid and dimethyl sulfoxide are named exemplarily as typical additives in transdermal therapeutic systems which represent a risk factor for classical printing technology. Surprisingly, not as to be expected by the expert, a disadvantageous change of drug content occurs upon the influence of temperature.
Particularly, by application of modern printing tools and machinery, impairment of drug content is practically excluded at short contact times.
The invention is represented in FIG. 1 in detail. However, instead of the diffusion matrix (2) shown, other typical elements of such pharmaceutical forms of application and element groups (reservoirs, diffusion membranes, etc.) may be used without impairing the inventive solution.
FIG. 1 shows a transdermal therapeutic system in cross-section with backing layer (1) divided up into printable thermoplastic layer (4) and diffusion-(and temperature-) barrier (5). The transdermal therapeutic system can also have a removable protecting layer (3).
The transdermal therapeutic system contains, therefore, the elements:
1. Backing layer, consisting of (4) and (5), with coding
2. Matrix
3. Removable protecting layer
4. Thermoplastic part of the backing layer with imprint
5. Diffusion barrier for the active agent (PETP).
In the present invention, coding is provided on the printable thermoplastic layer (4) of the backing layer. The coding consists of a locally different surface property, surface thickness or surface roughness of the backing layer. Coding on the backing layer may be generated by methods such as pressure, heat, ultrasound or abrasion. Such methods are known to those skilled in the art. The coding is typically performed after the transdermal therapeutic system has been formed.
Claims (2)
1. A transdermal therapeutic system comprising a backing layer and an active agent containing matrix layer, wherein the backing layer is provided with persistent information which consists of a coding formed by a locally different surface property, surface thickness or surface roughness of the backing layer, said backing layer consists of a laminate comprising an external layer and a layer facing the matrix, wherein the external layer is a low-melting thermoplastic material containing said information and the layer facing the skin is a higher melting thermoplastic material which protects the active agent containing matrix layer from damage during coding.
2. A method for manufacturing the transdermal therapeutic system according to claim 1, wherein the coding of the backing layer is performed after the completion of a process for preparing the transdermal therapeutic system, said coding is accomplished by the influence of pressure, heat, ultrasound or abrasion.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19519593A DE19519593C1 (en) | 1995-05-29 | 1995-05-29 | Transdermal therapeutic system with thermoplastic back layer |
| DE19519593 | 1995-05-29 | ||
| PCT/DE1996/000699 WO1996038187A1 (en) | 1995-05-29 | 1996-04-23 | Transdermal therapeutic system identified without printing inks and process for manufacturing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US6080421A true US6080421A (en) | 2000-06-27 |
Family
ID=7763092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/981,133 Expired - Lifetime US6080421A (en) | 1995-05-29 | 1996-04-23 | Transdermal therapeutic system identified without printing inks |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6080421A (en) |
| EP (1) | EP0828523B1 (en) |
| JP (1) | JP3293137B2 (en) |
| AT (1) | ATE204765T1 (en) |
| AU (1) | AU703765B2 (en) |
| CA (1) | CA2220341C (en) |
| DE (2) | DE19519593C1 (en) |
| DK (1) | DK0828523T3 (en) |
| ES (1) | ES2164239T3 (en) |
| WO (1) | WO1996038187A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030174321A1 (en) * | 2002-01-22 | 2003-09-18 | Cme Telemetrix Inc. | Device for reference measurement and photometric correction in non-invasive glucose measurement using near infrared spectroscopy |
| US20040043171A1 (en) * | 2002-08-30 | 2004-03-04 | Audett Jay Douglas | Multilaminate backing construction |
| US6851615B2 (en) | 1998-07-20 | 2005-02-08 | Noven Pharmaceuticals, Inc. | Method of individually tracking and identifying a drug delivery device |
| US20070116751A1 (en) * | 2003-04-17 | 2007-05-24 | Stefan Bracht | Medical active substance patch with reduced optical conspicuousness on the skin |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19736520A1 (en) * | 1997-08-22 | 1999-02-25 | Lohmann Therapie Syst Lts | New adhesive plaster containing electronic information |
| DE10039691C1 (en) * | 2000-08-14 | 2002-02-14 | Lohmann Therapie Syst Lts | Method for differentiating between active drugs and placebos in blind trials comprises marking drugs, their packages or drug systems with thermochromic material which becomes visible when heated or when cooled |
| DE102004028415B4 (en) * | 2003-08-07 | 2005-08-11 | Lts Lohmann Therapie-Systeme Ag | Dermal or transdermal therapeutic system containing a cover with barrier effect |
| EP2175398B1 (en) | 2008-10-08 | 2011-12-14 | Paul Hartmann Aktiengesellschaft | Medical product |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4359442A (en) * | 1980-01-08 | 1982-11-16 | Union Carbide Canada Limited | Process for the twin-web hot embossing of thermoplastic film |
| US4758434A (en) * | 1984-10-05 | 1988-07-19 | Hercon Laboratories Corporation | Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant |
| US5443727A (en) * | 1990-10-30 | 1995-08-22 | Minnesota Mining And Manufacturing Company | Articles having a polymeric shell and method for preparing same |
| US5593395A (en) * | 1987-08-07 | 1997-01-14 | Martz; Joel D. | Vapor permeable dressing |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4460368A (en) * | 1981-10-29 | 1984-07-17 | Almedco, Inc. | Trans-dermal medication system |
| WO1986000536A1 (en) * | 1984-07-06 | 1986-01-30 | Avery International Corporation | Bandage for sustained delivery of drugs |
| DE3762480D1 (en) * | 1986-08-23 | 1990-06-07 | Arno W Latzke | AGENT FOR APPLICATION OF TRANSDERMAL RESORBABLE ACTIVE SUBSTANCES. |
| DE3844250A1 (en) * | 1988-12-29 | 1990-07-05 | Minnesota Mining & Mfg | METHOD FOR PROVIDING A SURFACE OF A SUBSTRATE, WITH A RELEASE AGENT, AND THE OBJECT PRODUCED BY PROCEDURE |
| CA2127756C (en) * | 1993-07-19 | 2004-08-31 | Hitoshi Akemi | Package structure of drug-containing pressure-sensitive adhesive sheet |
| DE9409784U1 (en) * | 1994-06-10 | 1994-08-11 | Effner Biomet Gmbh, 12247 Berlin | Device for the transdermal application of active substances |
-
1995
- 1995-05-29 DE DE19519593A patent/DE19519593C1/en not_active Expired - Fee Related
-
1996
- 1996-04-23 AT AT96909973T patent/ATE204765T1/en active
- 1996-04-23 EP EP96909973A patent/EP0828523B1/en not_active Expired - Lifetime
- 1996-04-23 US US08/981,133 patent/US6080421A/en not_active Expired - Lifetime
- 1996-04-23 DK DK96909973T patent/DK0828523T3/en active
- 1996-04-23 AU AU53273/96A patent/AU703765B2/en not_active Expired
- 1996-04-23 JP JP53608196A patent/JP3293137B2/en not_active Expired - Lifetime
- 1996-04-23 WO PCT/DE1996/000699 patent/WO1996038187A1/en not_active Ceased
- 1996-04-23 CA CA002220341A patent/CA2220341C/en not_active Expired - Lifetime
- 1996-04-23 DE DE59607586T patent/DE59607586D1/en not_active Expired - Lifetime
- 1996-04-23 ES ES96909973T patent/ES2164239T3/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4359442A (en) * | 1980-01-08 | 1982-11-16 | Union Carbide Canada Limited | Process for the twin-web hot embossing of thermoplastic film |
| US4758434A (en) * | 1984-10-05 | 1988-07-19 | Hercon Laboratories Corporation | Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant |
| US5593395A (en) * | 1987-08-07 | 1997-01-14 | Martz; Joel D. | Vapor permeable dressing |
| US5443727A (en) * | 1990-10-30 | 1995-08-22 | Minnesota Mining And Manufacturing Company | Articles having a polymeric shell and method for preparing same |
Non-Patent Citations (3)
| Title |
|---|
| Chien, Development of Transdermal Controlled Release Delivery Systems: An Overview: Transdermal Delivery of Drugs. * |
| Volumn I, Edited by Kydonieus et al., CRC Press Inc., Boca Raton, Florida, Chapter 7, pp. 81 100 (Nov. 30, 1986. * |
| Volumn I, Edited by Kydonieus et al., CRC Press Inc., Boca Raton, Florida, Chapter 7, pp. 81-100 (Nov. 30, 1986. |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6851615B2 (en) | 1998-07-20 | 2005-02-08 | Noven Pharmaceuticals, Inc. | Method of individually tracking and identifying a drug delivery device |
| US20030174321A1 (en) * | 2002-01-22 | 2003-09-18 | Cme Telemetrix Inc. | Device for reference measurement and photometric correction in non-invasive glucose measurement using near infrared spectroscopy |
| US20040043171A1 (en) * | 2002-08-30 | 2004-03-04 | Audett Jay Douglas | Multilaminate backing construction |
| US20070281027A1 (en) * | 2002-08-30 | 2007-12-06 | Audett Jay D | Multilaminate backing construction |
| AU2003272237B2 (en) * | 2002-08-30 | 2009-11-19 | Alza Corporation | Embossable and writable multilaminate backing construction |
| US9078833B2 (en) | 2002-08-30 | 2015-07-14 | Alza Corporation | Multilaminate backing construction |
| US9248105B2 (en) | 2002-08-30 | 2016-02-02 | Alza Corporation | Multilaminate backing construction |
| US9522122B2 (en) | 2002-08-30 | 2016-12-20 | Alza Corporation | Multilaminate backing construction |
| US20070116751A1 (en) * | 2003-04-17 | 2007-05-24 | Stefan Bracht | Medical active substance patch with reduced optical conspicuousness on the skin |
| US10646453B2 (en) | 2003-04-17 | 2020-05-12 | Lts Lohmann Therapie-Systeme Ag | Medical active substance patch with reduced optical conspicuousness on the skin |
| US10653636B2 (en) | 2003-04-17 | 2020-05-19 | Lts Lohmann Therapie-Systeme Ag | Medical active substance patch with reduced optical conspicuousness on the skin |
| US11426358B2 (en) | 2003-04-17 | 2022-08-30 | Lts Lohmann Therapie-Systeme Ag | Medical active substance patch with reduced optical conspicuousness on the skin |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0828523A1 (en) | 1998-03-18 |
| CA2220341C (en) | 2005-06-21 |
| CA2220341A1 (en) | 1996-12-05 |
| AU703765B2 (en) | 1999-04-01 |
| EP0828523B1 (en) | 2001-08-29 |
| JP2000510095A (en) | 2000-08-08 |
| ES2164239T3 (en) | 2002-02-16 |
| DK0828523T3 (en) | 2001-12-17 |
| JP3293137B2 (en) | 2002-06-17 |
| WO1996038187A1 (en) | 1996-12-05 |
| AU5327396A (en) | 1996-12-18 |
| ATE204765T1 (en) | 2001-09-15 |
| DE19519593C1 (en) | 1996-08-29 |
| DE59607586D1 (en) | 2001-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2365528C (en) | Release strip with partible break to facilitate removal of adhesive coated strip | |
| CA2088358C (en) | Self-adhesive laminate for nails | |
| US6016618A (en) | Laminated article | |
| CN106237785B (en) | Labels, information-bearing media, methods of reducing carbon dioxide, and wristband buckles | |
| US6080421A (en) | Transdermal therapeutic system identified without printing inks | |
| WO1999039989A1 (en) | Cold seal package and method for making the same | |
| RU2009140660A (en) | SELF-ADHESIVE SHRINKING LABEL, PRODUCT WITH LABEL AND METHOD FOR APPLYING LABEL TO PRODUCT | |
| US20130101809A1 (en) | Sequentially Primed Printed Substrate | |
| WO2015048295A1 (en) | Tamper evident security labels | |
| EP3285677B1 (en) | Sheeted medical articles with adhered wristband | |
| US4086379A (en) | Multi-layered laminates | |
| JP5913808B2 (en) | Micro and / or nano structured packaging materials | |
| HU226029B1 (en) | A self-adhesive label | |
| Van Buskirk et al. | Scale-up of adhesive transdermal drug delivery systems | |
| JP3617552B2 (en) | Absorbent packaging structure | |
| US7473454B2 (en) | Laminate, a self-adhesive label web and a method for manufacturing | |
| JPH0623916A (en) | Coated pressure-sensitive self-adhesive carrier and its production | |
| EP1113061A2 (en) | Tamper-evident packaging tape | |
| US20070190125A1 (en) | Positioning feature for aiding use of film or strip product | |
| US20070031477A1 (en) | Methods and devices for holding a composition | |
| US8911772B2 (en) | Release liner or protective sheet having a slit covered by another layer for use in adhesive laminates | |
| JP2001314496A (en) | Patch base material sheet | |
| US20030228338A1 (en) | Label scent personal perfume applicator | |
| JPH04124276U (en) | polyethylene label | |
| AU2004201481A1 (en) | Label stock |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: HORSTMANN, MICHAEL, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HORSTMANN, MICHAEL;STEINBORN, PETER;REEL/FRAME:009188/0360 Effective date: 19971011 |
|
| AS | Assignment |
Owner name: LTS LOHMANN THERAPIE-SYSTEMS GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HORSTMANN, MICHAEL;REEL/FRAME:009616/0847 Effective date: 19981122 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |